Anwita Biosciences

Focus: Anwita Biosciences is a Series B-stage biotechnology company focused on antibodies and fusion proteins for cancer immunotherapy. The company is in early clinical development with a lean, pre-revenue profile.

Cancer Immunotherapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

SERIES B

Open Jobs

About Anwita Biosciences

AI assessmentNot Hiring

No open roles listed right now. Follow Anwita Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

JS014, Interleukin 21 and humanized anti-human serum albumin VHH antibody

Neoplasm Malignant

Phase 1

Clinical Trials (1)

NCT05296772Phase 1 First-in-human Study of JS014

Phase 1

Help build intelligence for Anwita Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage immuno-oncology platform focused on validated modalities (antibodies & fusion proteins) with potential for significant upside if Phase 1 programs advance
Based in Silicon Valley biotech hub (San Carlos, CA) with proximity to major pharma networks and venture capital ecosystem
Opportunity to shape drug development from early clinical stages in a lean, pre-commercial organization

Watch Out For

Only 1 open R&D role indicates minimal hiring momentum and potential resource constraints for a Series B biotech
Pre-revenue stage with no disclosed funding or cash position creates salary sustainability and runway risk
Extremely early pipeline (2 Phase 1 programs) with no Phase 2/3 data or clinical validation milestones in near term

Generated by Claude from Anwita Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

interleukin-21

Solid Tumor, Adult

Phase 1

AWT020

Advanced Cancer

Phase 1

Clinical Trials (1)

NCT06092580Phase 1 Study of AWT020 in Advanced Cancer

Phase 1